![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy, Treatment Duration and Safety of boceprevir/peginterferon/ribavirin in Treatment naive Patients With
Hepatitis C Virus Genotype 1 Infection: relationship to baseline fibrosis score
|
|
|
Reported by Jules Levin
AASLD 2013 Nov 1-5 Wash DC
Lawrence Serfaty,1 John Vierling,2 Fred Poordad,3 Steven Flamm,4 Bruce Bacon,5 Weiping Deng,6 Kenneth Koury,6 Karin Hagen,6 Katia Alves,6 Janice Wahl6
1Hopital Saint Antoine, APHP and INSERM UMR_938, Universite Pierre & Marie Curie, Paris, France; 2Baylor College of Medicine, St Lukes Episcopal Hospital, Houston, TX; 3The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX;
4Northwestern Feinberg School of Medicine, Chicago, IL; 5Saint Louis University School of Medicine, St Louis, MO; 6Merck & Co., Inc, Whitehouse Station, NJ USA
![AASLD1.gif](../images/120413/120413-7/AASLD1.gif)
![AASLD2.gif](../images/120413/120413-7/AASLD2.gif)
![AASLD3.gif](../images/120413/120413-7/AASLD3.gif)
![AASLD4.gif](../images/120413/120413-7/AASLD4.gif)
![AASLD5.gif](../images/120413/120413-7/AASLD5.gif)
![AASLD6.gif](../images/120413/120413-7/AASLD6.gif)
![AASLD7.gif](../images/120413/120413-7/AASLD7.gif)
![AASLD8.gif](../images/120413/120413-7/AASLD8.gif)
![AASLD9.gif](../images/120413/120413-7/AASLD9.gif)
![AASLD10.gif](../images/120413/120413-7/AASLD10.gif)
![AASLD11.gif](../images/120413/120413-7/AASLD11.gif)
![AASLD12.gif](../images/120413/120413-7/AASLD12.gif)
![AASLD13.gif](../images/120413/120413-7/AASLD13.gif)
![AASLD14.gif](../images/120413/120413-7/AASLD14.gif)
![AASLD15.gif](../images/120413/120413-7/AASLD15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|